COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma
- PMID: 36174622
- DOI: 10.1016/S1470-2045(22)00497-1
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma
Conflict of interest statement
GC reports advisory roles for Bayer, Eisai, Ipsen, and AstraZeneca. CC reports speaker fees for Eisai and Ipsen; advisory roles for Eisai and MSD; and grants from the European Union-FESR or FSE, PON Research and Innovation (2014-2020-DM 1062/2021). AD received educational support for congress attendance and consultancy fees from Roche; is supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; and receives grant funding from the European Association for the Study of the Liver (Andrew Burroughs Fellowship) and Cancer Research UK (RCCPDB- Nov21/100008). DJP received lecture fees from BMS, Roche, and EISAI; travel expenses from BMS and Bayer Healthcare; consulting fees from Mina Therapeutics, EISAI, Roche, DaVolterra, Ewopharma, and AstraZeneca; research funding (to institution) from MSD, GSK and BMS; grant funding from the Wellcome Trust Strategic Fund (PS3416) and from the Associazione Italiana per la Ricerca sul Cancro (AIRC MFAG Grant ID 25697); and support from the NIHR Imperial Biomedical Research Centre, the Imperial Experimental Cancer Medicine Centre (ECMC), and the Imperial College Tissue Bank. CAMF declares no competing interests.
Comment on
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical